Search This Blog

Thursday, October 8, 2015

Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer (NYSE:LLY)

FDA Breakthrough Therapy Designation has Potential to Expedite Development and Review



Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.